- Home
- IFRX
IFRX
InflaRx N.V.
as 11-11-2025 3:45pm EST
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
| Founded: | 2007 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 86.0M | IPO Year: | 2017 |
| Target Price: | $9.80 | AVG Volume (30 days): | 6.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.71 - $2.81 | Next Earning Date: | 11-07-2025 |
| Revenue: | $73,729 | Revenue Growth: | -62.71% |
| Revenue Growth (this year): | -51.15% | Revenue Growth (next year): | 1216.24% |
Latest InflaRx N.V. News
IFRX Breaking Stock News: Dive into IFRX Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
InflaRx Says Phase 2a Data Support Further Development of INF904 in 2 Skin Conditions
Associated Press Finance
a day ago
BC-Most Active Stocks
GlobeNewswire
a day ago
InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)
GlobeNewswire
4 days ago
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
Zacks
6 days ago
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates
Zacks
7 days ago
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
21 days ago
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Pharma Voice
5 months ago
COVID’s remaining biotech contenders navigate a dwindling market
Compare IFRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IFRX InflaRx N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.